Healthy Lifestyle Aids in Alzheimer Disease Risk Reduction


Those with ≥150 min per week in moderated or vigorous activities were low risk while those with less than 150 or sedentary activity were higher risk.

Richard J. Hodes, MD

Richard J. Hodes, MD

This article, "Combination of Healthy Lifestyle Factors Reduces Alzheimer Risk," was originally published in NeurologyLive.

A healthy lifestyle could be beneficial in reducing the risk of developing Alzheimer disease.

Data pooled from both the Chicago Health and Aging Project (CHAP) and the Rush and Memory and Aging Project (MAP) revealed that a combination of at least 4 of the 5 specified health behaviors—physical activity, not smoking, light-to-moderate alcohol consumption, high-quality diet, and cognitive activities—led to a lower risk of Alzheimer disease.

Funded by the National Institute on Aging (NIA), part of the National Institutes of Health (NIH), the results showed that risk of Alzheimer disease was 60% lower (pooled HR, 0.40; 95% CI, 0.28—0.56) in those with 4 to 5 health risk factors compared to participants with 0 to 1 healthy lifestyle factors.

Additionally, those with 2 to 3 healthy lifestyle factors had a 37% lower risk (pooled HR, 0.63; 95% CI, 0.47—0.84) than those with 0 to 1 healthy lifestyle risk factors.

During a median follow-up of 5.8 years in CHAP (n = 1,845) and 6.0 years in MAP (n = 920), 379 and 229 participants, respectively, had incident Alzheimer disease. The pooled HR of the disease across 2 cohorts was 0.73 (95% CI, 0.66—0.80) per each additional healthy lifestyle factor using multivariate-adjusted models.

When using a health score without light to moderate alcohol intake, the HRs of Alzheimer dementia per 1 healthy factor increase in the lifestyle score were 0.71 (95% CI, 0.59—0.86) in CHAP and 0.70 (95% CI, 0.61–0.81) in MAP, similar to the primary analysis. Similar results were found when we used never smoking as a healthy lifestyle factor.

Definition of healthy lifestyle score was on the basis of nonsmoking, ≥150 min per week of moderate/vigorous-intensity physical activity, light to moderate alcohol consumption, high-quality Mediterranean-DASH Diet Intervention for Neurodegenerative Delay Diet (MIND, upper 40%), and engagement in late-life cognitive activities (upper 40%), all between an overall score of 0-5.

Researchers used Cox proportional hazard models for each cohort to estimate the HR and 95% CI of the lifestyle score with AD, and a random-effect meta-analysis to pool the results.

Healthy lifestyle factors were also narrowed down in into low- and high-risk categories.

Those with ≥150 min per week in moderated or vigorous activities were low risk while those with less than 150 or sedentary activity were higher risk.

Cognitive activity in the upper two-fifths, or the highest 40%, of the distribution were low-risk and those in the bottom three-fifths of the distribution were high-risk.

Increasing physical activity, along with blood pressure management and cognitive training was “encouraging although inclusive” for preventing AD in a 2017 research review commissioned by the NIA.

A high-quality MIND diet, which combines the Mediterranean diet and Dietary Approaches to Stop Hypertension (DASH) diet, was also recommended.

A study published by the National Eye Institute (NEI) in early April suggested that dietary factors can play a role in slowing cognitive decline. More specifically, diets that include high consumption of vegetables, whole grains, fish, and olive oil correlate with higher cognitive function.

Research showed that the odds ratio (OR) for cognitive impairment in patients with the greatest adherence to the alternative Mediterranean diet (aMED) was 0.36 (P = .0001) for a Modified Mini-Mental State Examination (3MS) score <80, 0.56 for composite score (P = .001), as well as 0.56 for Telephone Interview Cognitive Status-Modified (TICS-M) score <30 and 0.48 for composite score (P <.0001 for both) compared with those in the lowest adherence tertile.

“The findings strengthen the association between healthy behaviors and lower risk and add to the basis for controlled clinical trials to directly test the ability of interventions to slow or prevent development of Alzheimer’s disease,” Richard J. Hodes, MD, director, NIA, said in a statement.

Related Videos
Primary Care Roles in Alzheimer Diagnosis, with Theresa Sivers-Teixeira, MSPA, PA-C
Getting Black Men Involved in Their Health Care, Clinical Research
Patient Involvement in Advanced HF Treatment, with Ashley Malliett, DMSc, MPAS, PA-C
Aaron Henry, PA-C, MSHS: Regaining Black Male Patient Trust in the Doctor's Office
How to Adequately Screen for and Treat Cognitive Decline in Primary Care
Tailoring Chest Pain Diagnostics to Patients, with Kyle Fortman, PA-C, MBA
James R. Kilgore, DMSc, PhD, PA-C: Cognitive Decline Diagnostics
Solutions to Prevent Climate Change-Related Illness, with Janelle Bludhorn, PA-C
Kyle Fortman, PA-C, MBA: Troponin and Heart Injury Risk Screening Recommendations
What Should the American Academy of Physician Associates Focus on in 2025?
© 2024 MJH Life Sciences

All rights reserved.